IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). We are currently focused on exploiting new mechanisms of action to treat cancer diseases. Multiple myeloma and small cell lung cancer are our priorities.
Our efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, we have built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.
IDP Pharma was founded in 2015 and the company is located in the Scientific Park of Barcelona (PCB), Spain.